POLB vs. REDX, SBTX, ETX, TRX, FUM, COS, C4XD, DDDD, OKYO, and AOR
Should you be buying Poolbeg Pharma stock or one of its competitors? The main competitors of Poolbeg Pharma include Redx Pharma (REDX), SkinBioTherapeutics (SBTX), e-therapeutics (ETX), Tissue Regenix Group (TRX), Futura Medical (FUM), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), OKYO Pharma (OKYO), and AorTech International (AOR). These companies are all part of the "biotechnology" industry.
Poolbeg Pharma vs.
Poolbeg Pharma (LON:POLB) and Redx Pharma (LON:REDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, community ranking, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.
1.2% of Poolbeg Pharma shares are owned by institutional investors. Comparatively, 72.7% of Redx Pharma shares are owned by institutional investors. 24.7% of Poolbeg Pharma shares are owned by company insiders. Comparatively, 18.4% of Redx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Poolbeg Pharma's average media sentiment score of 0.00 equaled Redx Pharma'saverage media sentiment score.
Redx Pharma received 153 more outperform votes than Poolbeg Pharma when rated by MarketBeat users. Likewise, 73.56% of users gave Redx Pharma an outperform vote while only 0.00% of users gave Poolbeg Pharma an outperform vote.
Poolbeg Pharma has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500. Comparatively, Redx Pharma has a beta of -0.53, suggesting that its stock price is 153% less volatile than the S&P 500.
Redx Pharma has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.
Poolbeg Pharma's return on equity of -32.56% beat Redx Pharma's return on equity.
Summary
Redx Pharma beats Poolbeg Pharma on 6 of the 11 factors compared between the two stocks.
Get Poolbeg Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Poolbeg Pharma Competitors List
Related Companies and Tools
This page (LON:POLB) was last updated on 3/29/2025 by MarketBeat.com Staff
Buy POLB Stock Free POLB Stock Alerts